Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Israel biotechnology company Can-Fite BioPharma has partnered with the Lewis Katz School of Medicine at Temple University in the US to test the anti-viral activity of Piclidenoson against Covid-19.
Initially, the project, led by Dr Kamel Khalili, will evaluate the drug’s effect on coronaviruses viral load in a mammalian cell model system.
Piclidenoson is undergoing a Phase III clinical trial to treat rheumatoid arthritis. Previously, the drug demonstrated anti-viral activity against HIV and HCC, which are single-stranded RNA viruses.